Bio-Thera Solutions, Ltd.SSE: 688177

Announcement on Share Reduction Plan for Shareholders

Apr 24, 2025 · Issued by Bio-Thera Solutions, Ltd. via Shanghai Stock Exchange

Filed with SSE · Apr 24, 2025

On 6ix: 6ix.com/news/announcement-on-share-reduction-plan-for-shareholders-46

Announcement on Share Reduction Plan for Shareholders

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Bio-Thera Solutions, Ltd. on 6ix

Earlier from Bio-Thera Solutions

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trial of BAT7111 for InjectionApr 22, 2025
Announcement on Election of Employee Representative Director for the Third Board of DirectorsApr 19, 2025
Bio-Thera Solutions Presents Clinical Data for multiple products at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingApr 14, 2025
Notice on Convening the 2024 Annual General MeetingApr 9, 2025
Announcement on the Latest Development of BAT1806 (Tocilizumab) BusinessApr 2, 2025

Later from Bio-Thera Solutions

Report for Q1 2025Apr 29, 2025
Announcement on Completing the Term Change and Election of the Board of Directors and Appointment of Senior Management Members, Securities Affairs Representatives, and Head of Internal AuditMay 1, 2025
Announcement on Adjusting the Development Strategy of BAT3306 (Pembrolizumab)May 23, 2025
Announcement on FDA Approval for BAT2206 (Ustekinumab) Injection in the United StatesMay 24, 2025
Bio-Thera Solutions and Hikma Pharmaceuticals announce FDA approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) InjectionMay 27, 2025

All Bio-Thera Solutions news releases

Follow Bio-Thera Solutions into a list and get an email when it puts out news.

Follow Bio-Thera Solutions